DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment

Information source: University of Tartu
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Early Onset Neonatal Sepsis

Phase: N/A

Status: Completed

Sponsored by: University of Tartu

Official(s) and/or principal investigator(s):
Irja Lutsar, MD, PhD, Study Chair, Affiliation: University of Tartu


A prospective two-center antibiotic regimen switch study will be conducted to compare the

clinical efficacy of two antibiotic regimens - penicillin/gentamicin versus

ampicillin/gentamicin - in the empirical treatment of early onset neonatal sepsis. The

influence of either regimen on bowel colonization pattern and on the development of antibiotic resistance of gut microflora will also be assessed. The primary endpoint is the need for a change in antibacterial treatment within 72 hours of therapy, based on pre-defined criteria. Secondary endpoints will be the incidence rate and etiology of early and late onset neonatal sepsis and susceptibility pattern of causative microorganisms; mortality rate within 60 days; duration of hospitalization in NICU; duration of artificial ventilation; colonization pattern and susceptibility of colonizing bacteria (including resistance to empiric antibiotic regimen).

Clinical Details

Official title: Comparative Study of Two Antibiotic Regimen - Penicillin G/Gentamicin Versus Ampicillin/Gentamicin in Empirical Treatment of Early Onset Neonatal Septicaemia

Study design: Observational Model: Cohort, Time Perspective: Prospective

Detailed description: A prospective randomized two-centre antibiotic regimen switch study will be conducted in the NICU-s of Tartu University Clinics and of Tallinn Children's Hospital. Initially all patients who need empiric treatment for early onset neonatal sepsis (as defined by Schrag et al. 2002) in Tartu will be treated with penicillin/gentamicin and those in Tallinn with ampicillin/gentamicin. When half of the needed subjects have been recruited, departmental antibiotic regimen will be switched so that ampicillin is used in Tartu and penicillin in Tallinn. Based on the present patient population and hospitalization rate, about 120-150 babies, eligible for the study will be admitted to either units every a year. In all subjects predefined pre- and intranatal risk factors of infection will be registered. During the NICU stay laboratory and clinical signs of infection, need for respiratory support and vasoactive therapy, enteral and parenteral nutrition will be recorded. Blood, CSF and urine cultures will be taken according to the routine of the ward but certainly before every change in antibacterial treatment. For colonization studies nasopharyngeal or tracheal and anal swabs will be collected from all neonates admitted during the study period on admission and thereafter biweekly until discharge from the NICU or until the 60th day of treatment. A separate protocol will be followed for microbiological investigations. The endpoints: The primary endpoint is the need for a change in antibacterial treatment within 72 hours. In discussions with clinical experts in both wards the following criteria for the change in antibacterial treatment were defined: 1. proven or suspected meningitis or abdominal infection 2. isolation from a relevant site of the mother or an infant of a microorganism, resistant to initial empiric treatment regimen in babies with early onset neonatal sepsis or septic shock 3. deterioration of the clinical status on initial antibiotic regimen and suspected/proven neonatal sepsis 4. suspected/proven late onset sepsis or nosocomial infection (defined as the development of clinical/ laboratory signs of infection at postnatal age of 72 hours or more) 5. other situations, where the treating physician considers change in antibiotic regimen

necessary - the reasons will be recorded in the case report form Patients, who die

before 72 hours or in whom the antibacterial therapy is changed for other than the above-mentioned reasons, will be handled as treatment failures. Secondary endpoints will be the following:

- incidence rate and etiology of early and late onset neonatal sepsis, susceptibility

pattern of causative microorganisms

- incidence rate and etiology of nosocomial sepsis, susceptibility pattern of causative


- mortality rate within 60 days

- duration of hospitalization in NICU stay

- duration of artificial ventilation

- colonization pattern and susceptibility of colonizing bacteria (including resistance to

empiric antibiotic regimen).


Minimum age: N/A. Maximum age: 72 Hours. Gender(s): Both.


Inclusion Criteria:

- All neonates, admitted to the study NICU-s at the age of less than 72 hours and

needing early empiric antibiotic treatment according to pre-defined criteria as described by Schrag et al. (2002) Exclusion Criteria:

- Subjects, who on clinical or other indications (e. g. suspected/proven meningitis or

abdominal cavity infection, isolation of resistant bacteria from the mother of a neonate with severe sepsis) need antibiotic treatment other than specified in the study protocol and infants who are likely to be transferred to other units within 24 hours.

Locations and Contacts

Tallinń's Childrens Hospital, Paediatric Intensive Care Unit, Tallinn, Estonia

Tartu University Clinics, Department of Paediatric Intensive Care, Tartu 50411, Estonia

Additional Information

Related publications:

Schrag S., Gorwitz R., Fultz-Butts K., Schuchat A., Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC. August 16, 2002 / 51(RR11), 1-22 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5111a1.htm:

Starting date: August 2006
Last updated: May 27, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017